Stout performed private company stock valuations for an emerging biotechnology company. When the company pivoted toward a planned initial public offering in 2021 or 2022, our work grew to include numerous complex securities valuations.

We performed financial instrument valuations under ASC 480, 718, 815, and 825. The complexity of the debt and equity accounting issues that governed the valuation needs warranted close collaboration with the company’s technical accounting consultants, auditors, and the auditors’ valuation specialists. In a volatile market for biotech fundraising, we assisted as the company’s liquidity plans changed multiple times, helping with valuations needed for an S-1, an S-4 for a planned special purpose acquisition corporation deal, and a second confidential S-1 filing.